Status:

TERMINATED

Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection

Lead Sponsor:

NYU Langone Health

Conditions:

Calcific Tendinitis

Eligibility:

All Genders

18-90 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to determine the efficacy of barbotage therapy by comparing the clinical and sonographic changes in patients that solely receive barbotage to patients receiving the standa...

Detailed Description

Calcific tendonitis is a condition caused by calcium deposits building up in a person's muscles or tendons. If calcium builds up in an area, a person may feel pain and discomfort there. The purpose of...

Eligibility Criteria

Inclusion

  • Must be at least 18 years of age and younger than 90 years of age
  • Diagnosed with calcific tendonitis and ruled out other shoulder-related pathologies
  • Failed 1st line therapy (physical therapy and cortisone injection)
  • Intention to receive barbotage with cortisone as standard of care
  • 3 or more months of shoulder pain
  • Finding of one or more calcifications ≥5 mm in size on either sonogram or radiograph, located on the supraspinatus tendon
  • Positive Hawkin's test or Neer's sign for impingement

Exclusion

  • Legally incompetent or mentally impaired (e.g. minors, Alzheimer's subjects, dementia, etc.)
  • Osteoarthritis of the glenohumeral joint of the affected shoulder
  • Previous surgery or barbotage to the affected shoulder
  • History of prior allergic/hypersensitivity reactions related to the study medication
  • Shoulder instability, glenohumeral arthritis, AC pathology, inflammatory arthropathy, fibromyalgia, frozen shoulder or cervical radiculopathy
  • Sub-acromial injection with a corticosteroid or treatment by ESWT during the last 3 months before inclusion
  • Younger than 18 years of age or older than 90
  • Any patient considered a vulnerable subject

Key Trial Info

Start Date :

December 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 23 2022

Estimated Enrollment :

4 Patients enrolled

Trial Details

Trial ID

NCT04126278

Start Date

December 1 2020

End Date

August 23 2022

Last Update

January 5 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

NYU Langone Health

New York, New York, United States, 10016